Lexeo Therapeutics (NASDAQ:LXEO) Earns “Buy” Rating from Chardan Capital

Lexeo Therapeutics (NASDAQ:LXEO)‘s stock had its “buy” rating reiterated by stock analysts at Chardan Capital in a report issued on Tuesday,Benzinga reports. They presently have a $17.00 price objective on the stock. Chardan Capital’s price target points to a potential upside of 120.21% from the stock’s previous close.

A number of other equities analysts also recently issued reports on the company. Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Oppenheimer reissued an “outperform” rating and set a $20.00 target price on shares of Lexeo Therapeutics in a research report on Wednesday, December 10th. HC Wainwright cut their target price on shares of Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday. Cantor Fitzgerald began coverage on shares of Lexeo Therapeutics in a research report on Monday, December 1st. They set an “overweight” rating and a $19.00 target price on the stock. Finally, Guggenheim assumed coverage on Lexeo Therapeutics in a report on Wednesday, October 15th. They issued a “buy” rating and a $30.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Lexeo Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $19.00.

Lexeo Therapeutics Stock Up 3.9%

Shares of Lexeo Therapeutics stock opened at $7.72 on Tuesday. The stock has a market cap of $563.48 million, a price-to-earnings ratio of -2.86 and a beta of 1.75. Lexeo Therapeutics has a twelve month low of $1.45 and a twelve month high of $10.99. The company’s fifty day moving average is $9.45 and its 200 day moving average is $7.13.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.15. As a group, equities analysts anticipate that Lexeo Therapeutics will post -3.14 earnings per share for the current fiscal year.

Insider Activity

In other Lexeo Therapeutics news, insider Eric Adler sold 3,382 shares of the company’s stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $8.94, for a total value of $30,235.08. Following the completion of the sale, the insider owned 73,261 shares of the company’s stock, valued at $654,953.34. This represents a 4.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Tai Sandi See sold 3,888 shares of the stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $8.94, for a total transaction of $34,758.72. Following the transaction, the insider owned 65,862 shares in the company, valued at $588,806.28. The trade was a 5.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 24,646 shares of company stock worth $221,037. 5.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Lexeo Therapeutics

Hedge funds have recently made changes to their positions in the business. CWM LLC boosted its stake in shares of Lexeo Therapeutics by 150.3% in the 2nd quarter. CWM LLC now owns 10,351 shares of the company’s stock valued at $42,000 after purchasing an additional 6,216 shares in the last quarter. Ethic Inc. bought a new stake in Lexeo Therapeutics in the second quarter worth $44,000. Cerity Partners LLC bought a new stake in Lexeo Therapeutics in the second quarter worth $50,000. Intech Investment Management LLC boosted its position in Lexeo Therapeutics by 20.7% during the second quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock valued at $55,000 after buying an additional 2,342 shares during the period. Finally, Vanguard Personalized Indexing Management LLC bought a new position in shares of Lexeo Therapeutics during the second quarter valued at about $60,000. 60.67% of the stock is currently owned by institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.